Skip to main content
Stroke Outcomes and Hyperacute Treatment Utilization in Multiple Sclerosis.
High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics.
Ethical considerations in the treatment of multiple sclerosis fatigue.
Ocrelizumab exposure in the second trimester of pregnancy without neonatal B-cell depletion.
Dare we mention the C-word?
Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.
Is multiple sclerosis a risk factor for infections?
The future of microbiome research in neuroinflammatory disorders.
The COVID-19 pandemic and the use of MS disease-modifying therapies.